RxDoctor Payments Data

Jodie Barkin, MD

Gastroenterology · Miami, FLNPI 1669771259

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Medtronic at 45.2% of the total. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$100,822in general payments, 2019–2025

Across 128 payments — averaging $787.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$46K
  • Amgen$13K
  • AbbVie$13K
  • Aimmune Therapeutics, Inc.$9K
  • Iterative Scopes, Inc.$6K
  • Nestle Healthcare Nutrition Inc.$6K
  • plus $8K from 12 others
$57,922in research payments, 2019–2025

Across 24 payments — averaging $2413.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$27K
  • Takeda Pharmaceuticals U.S.A., Inc.$27K
  • Medtronic$4K

What the payments were for

  • Consulting fees$55,98556%
  • Speaking & faculty fees$27,60527%
  • Travel & lodging$12,58112%
  • Food & beverage$4,6515%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$100,822 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida →

Medicare billing

Part B allowed, 2024
$92,847
Medicare patients
354
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase62$362,064
Omeprazole208$4,208
ClenpiqSod Picosulf/Mag Ox/Citric Ac12$2,098
Pantoprazole Sodium114$1,675
Sucralfate42$1,663
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl79$1,149
Dicyclomine Hcl12$661
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg21$352
Famotidine20$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$12,832$362,06462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →